MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to...

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric...